Abstract
The perturbations of the cytokine signaling pathway play an important role in lymphoid/hematopoietic tumors. Aberrant promoter methylation is the major mechanism of gene silencing in tumors. We examined 150 lymphoid/hematopoietic tumors or potential premalignant specimens, 55 control specimens and 12 EBV-transformed B lymphoblastoid cultures and 10 lymphoma/leukemia (L/L) or multiple myeloma (MM) cell lines for the methylation (and, in cell lines, of the expression status) of three genes involved in the cytokine signaling pathway. The genes were: SHP1, a protein tyrosine phosphatase; SYK, a protein kinase; and SOCS1, a suppressor of cytokine signaling. Our major findings were: (1) one or more of the three genes was frequently methylated in L/L and MM cell lines and there was good concordance (90–100%) between methylation and loss of gene expression; (2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 protein and downregulation of phosphorylated STAT3 in L/L cell lines; (3) all 55 control specimens and the lymphoblastoid cultures were negative for methylation of the three genes; (4) non-Hodgkin's lymphomas (100%), and leukemias (94%) had almost universal methylation of SHP1 and relatively less frequent (<30%) methylation of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent methylation of SHP1 (<20%), and occasional methylation of SOCS1 and SYK; and (6) comparable methylation frequencies for SOCS1 were observed in MM and MGUS, suggesting that SOCS1 methylation is an early event in MM pathogenesis. At least one gene was methylated in 119 of 130 (93%) of the malignant and 12 of 20 (60%) of the MGUS samples. Our findings demonstrate that the perturbations of cytokine signaling via silencing of these three genes are almost universal in lymphoid/hematopoietic tumors but the patterns of gene methylated for L/L and plasma cell dyscrasias are different.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bowman T, Garcia R, Turkson J and Jove R . (2000). Oncogene, 19, 2474–2488.
Bromberg J . (2002). J. Clin. Invest., 109, 1139–1142.
Chim CS, Wong KY, Loong F and Srivastava G . (2004). Leukemia, 18, 356–358.
Galm O, Yoshikawa H, Esteller M, Osieka R and Herman JG . (2003). Blood, 101, 2784–2788.
Ganju RK, Brubaker SA, Chernock RD, Avraham S and Groopman JE . (2000). J. Biol. Chem., 275, 17263–17268.
Goodman PA, Burkhardt N, Juran B, Tibbles HE and Uckun FM . (2003). Oncogene, 22, 2504–2514.
Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, Bauters F, Fenaux P and Quesnel B . (2001). Blood, 98, 244–246.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.
Jebbink J, Bai X, Rogers BB, Dawson DB, Scheuermann RH and Domiati-Saad R . (2003). J. Mol. Diagn., 5, 15–20.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E and Thun MJ . (2004). CA Cancer. J. Clin., 54, 8–29.
Jones PA and Baylin SB . (2002). Nat. Rev. Genet., 3, 415–428.
Krebs DL and Hilton DJ . (2000). J. Cell Sci., 113 (Part 16), 2813–2819.
Kuehl WM and Bergsagel PL . (2002). Nat. Rev. Cancer, 2, 175–187.
Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, Plevak MF and Melton LJ . (2003). Blood, 102, 3759–3764.
Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N, Kondo E, Takahashi K, Tsuchiyama J, Tanimoto M, Shimizu K and Akagi T . (2002). Cancer Res., 62, 6390–6394.
O'Shea JJ, Gadina M and Schreiber RD . (2002). Cell, 109 (Suppl), S121–S131.
Shivapurkar N, Harada K, Reddy J, Scheuermann RH, Xu Y, McKenna RW, Milchgrub S, Kroft SH, Feng Z and Gazdar AF . (2002a). Lancet, 359, 851–852.
Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyooka S, Minna JD, Chaudhary PM and Gazdar AF . (2002b). Oncogene, 21, 8510–8514.
Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, Chaudhary PM and Gazdar AF . (2002c). Cancer Biol. Ther., 1, 65–69.
Turner M, Schweighoffer E, Colucci F, Di Santo JP and Tybulewicz VL . (2000). Immunol. Today, 21, 148–154.
Wu C, Sun M, Liu L and Zhou GW . (2003). Gene, 306, 1–12.
Yasukawa H, Sasaki A and Yoshimura A . (2000). Annu. Rev. Immunol., 18, 143–164.
Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC and Herman JG . (2001). Nat. Genet., 28, 29–35.
Young LS and Murray PG . (2003). Oncogene, 22, 5108–5121.
Yuan Y, Mendez R, Sahin A and Dai JL . (2001). Cancer Res., 61, 5558–5561.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by Grant 5U01CA8497102 from Early Detection Research Network (EDRN), National Cancer Institute, Bethesda, MD, USA
Rights and permissions
About this article
Cite this article
Reddy, J., Shivapurkar, N., Takahashi, T. et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24, 732–736 (2005). https://doi.org/10.1038/sj.onc.1208032
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208032
Keywords
This article is cited by
-
Alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues in obese women
BMC Endocrine Disorders (2023)
-
SHP1 regulates a STAT6–ITGB3 axis in FLT3ITD-positive AML cells
Leukemia (2020)
-
Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development
Leukemia (2016)
-
Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy
Biomarker Research (2013)
-
JAK/STAT signaling in hematological malignancies
Oncogene (2013)
